Resources Repository
-
GuidelinesPublication 2016Second Panel on Cost-Effectiveness in Health and Medicine
This article provides an overview of the main recommendations of the 2016 Second Panel on …
This article provides an overview of the main recommendations of the 2016 Second Panel on Cost-Effectiveness in Health and Medicine. In 1993, the U.S. Public Health Service convened the first panel of experts to review the state of cost-effectiveness analysis and to develop guidelines for its use in health, to improve quality and promote comparability. Scientists and scholars in economics, clinical medicine, ethics, and statistics met to share expertise and develop recommendations by consensus. The…
Evidence Synthesis | Priority Setting/Ethics | Technology Assessment | Health/Medicine | Costing Methods | Cost-Effectiveness Analysis | North America -
ReviewPublication 2016Using Economic Evidence to Set Healthcare Priorities in LMIC
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks …
Policy makers in low-income and lower-middle-income countries (LMICs) are increasingly looking to develop ‘evidence-based’ frameworks for identifying priority health interventions. This paper synthesizes and appraises the literature on methodological frameworks – which incorporate economic evaluation evidence – for the purpose of setting healthcare priorities in LMICs. A systematic search of Embase, MEDLINE, Econlit and PubMed identified 3968 articles with a further 21 articles identified through manual searching. A total of 36 papers were eligible for inclusion.…
Priority Setting/Ethics | Technology Assessment | Benefit-Cost Analysis | Health/Medicine | Cost-Effectiveness Analysis | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
GuidelinesPublication 2015USPSTF Procedure Manual
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the …
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the Task Force to ensure that its recommendations are scientifically sound, reproducible, and well documented. The Manual provides a high-level description of the Task Force’s structure, governance, and processes for selecting topics, reviewing evidence, soliciting and responding to public input, and arriving at a recommendation. It is intended as a guide for anyone who is interested in the Task Force, Task…
Evidence Synthesis | Priority Setting/Ethics | Technology Assessment | Health/Medicine | Health Systems | Policy/Regulation | Government/Law | North America -
ArticlePublication 2015Broader Economic Impact of Vaccination: Reviewing and Appraising the Strength of Evidence
Economic evaluations of public health programs such as immunization often consider only direct health benefits and …
Economic evaluations of public health programs such as immunization often consider only direct health benefits and medical cost savings. Evidence linking immunization to important benefits in indicators such as childhood development, household behavior, and other macro-economic data are unclear. A conceptual framework of the pathways between immunization and these broader economic benefits was developed through expert consultation. The authors obtained articles from previous reviews, snowballing, and expert consultation, and associated them with one of the pathways and assessed them using modified Grading…
Evidence Synthesis | Priority Setting/Ethics | Benefit-Cost Analysis | Health/Medicine | Preferences/Values | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Social Determinants | Economics/Finance | Education/Labor -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Evidence Synthesis | Priority Setting/Ethics | Technology Assessment | Health/Medicine | Mathematical Models | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Government/Law | North America -
ReviewPublication 2023Adaptive Health Technology Assessment: A Scoping Review of Methods
This study explores adaptive health technology assessment (aHTA) as an expedited alternative to full HTA, …
This study explores adaptive health technology assessment (aHTA) as an expedited alternative to full HTA, aiming to support universal health coverage by leveraging HTA evidence from other settings. The scoping review identified and mapped existing aHTA methods, examining their triggers, strengths, and weaknesses. Methods included searching HTA agencies' and networks' websites, and published literature, with findings narratively synthesized. The review found aHTA methods in 20 countries and one HTA network across the Americas, Europe, Africa,…
Priority Setting/Ethics | Technology Assessment | Health/Medicine | Cost-Effectiveness Analysis | Global -
ReviewPublication 2023Inclusion of Environmental Spillovers in Applied Economic Evaluations of Healthcare Products
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and …
This review examines the inclusion of environmental spillovers in economic evaluations of healthcare products and health technology assessments (HTA). Environmental spillovers, such as CO2 emissions, water and energy consumption, and waste disposal, significantly impact human and planetary health but are often excluded from HTAs. The review's objective is to identify economic evaluations and guidelines incorporating environmental dimensions. Methods included electronic searches of PubMed, Scopus, and EMBASE, as well as official health agencies' guidelines. Documents were…
Evidence Synthesis | Technology Assessment | Health/Medicine | Cost-Effectiveness Analysis | Environmental Health | Climate/Environment | Global -
ReviewPublication 2023Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: ISPOR Special Interest Group Report
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes …
This study addresses the gaps and challenges in the value assessment of biosimilars and proposes potential approaches to mitigate them. A multidisciplinary team of biosimilar experts conducted a systematic review of literature and engaged in review rounds to identify these challenges. The article suggests that health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and conduct price comparisons for biosimilars reimbursed for the same indication as the reference biologic. In cases…
Evidence Synthesis | Technology Assessment | Health/Medicine | Preferences/Values | Policy/Regulation -
ArticlePublication 2023Evaluation of Diversity of Clinical Trials Informing Health Technology Assessments in the United States: A 5-Year Analysis of Institute for Clinical and Economic Review Assessments
The study assessed the diversity of clinical trials informing assessments by the Institute for Clinical …
The study assessed the diversity of clinical trials informing assessments by the Institute for Clinical and Economic Review (ICER) over five years (2017-2021). It conducted a cross-sectional analysis of 208 pivotal trials across 31 conditions. Findings revealed inadequate representation of racial/ethnic minorities and older adults, with Blacks/African Americans, American Indians/Alaska Natives, and Hispanics/Latinos being notably underrepresented. Whites, Asians, and Native Hawaiian/Other Pacific Islanders were adequately represented. US-based trials better represented Blacks/African Americans and Hispanics/Latinos but…
Evidence Synthesis | Technology Assessment | Health/Medicine | North America